James T Thackeray1, Robert A deKemp, Rob S Beanlands, Jean N DaSilva. 1. Molecular Function & Imaging Program, National Cardiac PET Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada, jdasilva@ottawaheart.ca.
Abstract
BACKGROUND: Diabetes is associated with increased sympathetic activity, elevated norepinephrine, impaired heart rate variability, and the added risk of cardiovascular mortality. The temporal development of sympathetic neuronal dysfunction, response to therapy, and relation to ventricular function is not well characterized. METHODS AND RESULTS: Sympathetic neuronal integrity was serially investigated in high fat diet-fed streptozotocin diabetic rats using [(11)C]meta-hydroxyephedrine (HED) positron emission tomography at baseline, 8 weeks of diabetes, and after a further 8 weeks of insulin or insulin-sensitizing metformin therapy. Myocardial HED retention was reduced in diabetic rats (n = 16) compared to non-diabetics (n = 6) at 8 weeks by 52-57% (P = .01) with elevated plasma and myocardial norepinephrine levels. Echocardiography pulse-wave Doppler measurements demonstrated prolonged mitral valve deceleration and increased early-to-atrial filling velocity, consistent with diastolic dysfunction. Insulin but not metformin evoked recovery of HED retention and plasma norepinephrine (P < .05), whereas echocardiography measurements of diastolic function were not improved by either treatment. Relative expressions of norepinephrine reuptake transporter and β-adrenoceptors were lower in metformin-treated as compared to insulin-treated diabetic and non-diabetic rats. Diabetic rats exhibited depressed heart rate variability and impaired diastolic function which persisted despite insulin treatment. CONCLUSIONS: HED imaging provides sound estimation of sympathetic function. Effective glycemic control can recover sympathetic function in diabetic rats without the corresponding recovery of echocardiography indicators of diastolic dysfunction. HED positron emission tomography imaging may be useful in stratifying cardiovascular risk among diabetic patients and in evaluating the effect of glycemic therapy on the heart.
BACKGROUND:Diabetes is associated with increased sympathetic activity, elevated norepinephrine, impaired heart rate variability, and the added risk of cardiovascular mortality. The temporal development of sympathetic neuronal dysfunction, response to therapy, and relation to ventricular function is not well characterized. METHODS AND RESULTS: Sympathetic neuronal integrity was serially investigated in high fat diet-fed streptozotocindiabeticrats using [(11)C]meta-hydroxyephedrine (HED) positron emission tomography at baseline, 8 weeks of diabetes, and after a further 8 weeks of insulin or insulin-sensitizing metformin therapy. Myocardial HED retention was reduced in diabeticrats (n = 16) compared to non-diabetics (n = 6) at 8 weeks by 52-57% (P = .01) with elevated plasma and myocardial norepinephrine levels. Echocardiography pulse-wave Doppler measurements demonstrated prolonged mitral valve deceleration and increased early-to-atrial filling velocity, consistent with diastolic dysfunction. Insulin but not metformin evoked recovery of HED retention and plasma norepinephrine (P < .05), whereas echocardiography measurements of diastolic function were not improved by either treatment. Relative expressions of norepinephrine reuptake transporter and β-adrenoceptors were lower in metformin-treated as compared to insulin-treated diabetic and non-diabeticrats. Diabeticrats exhibited depressed heart rate variability and impaired diastolic function which persisted despite insulin treatment. CONCLUSIONS:HED imaging provides sound estimation of sympathetic function. Effective glycemic control can recover sympathetic function in diabeticrats without the corresponding recovery of echocardiography indicators of diastolic dysfunction. HED positron emission tomography imaging may be useful in stratifying cardiovascular risk among diabeticpatients and in evaluating the effect of glycemic therapy on the heart.
Authors: James T Thackeray; Maryam Parsa-Nezhad; Miran Kenk; Stephanie L Thorn; Maria Kolajova; Rob S B Beanlands; Jean N DaSilva Journal: Nucl Med Biol Date: 2011-08-09 Impact factor: 2.408
Authors: M J Stevens; D M Raffel; K C Allman; F Dayanikli; E Ficaro; T Sandford; D M Wieland; M A Pfeifer; M Schwaiger Journal: Circulation Date: 1998-09-08 Impact factor: 29.690
Authors: Rodica Pop-Busui; Ian Kirkwood; Helena Schmid; Victor Marinescu; Justin Schroeder; Dennis Larkin; Elina Yamada; David M Raffel; Martin J Stevens Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Hendrik J Harms; Stefan de Haan; Paul Knaapen; Cornelis P Allaart; Mischa T Rijnierse; Robert C Schuit; Albert D Windhorst; Adriaan A Lammertsma; Marc C Huisman; Mark Lubberink Journal: EJNMMI Res Date: 2014-09-26 Impact factor: 3.138